Printer Friendly

VIRATEK REPORTS SECOND QUARTER SALES AND EARNINGS

 VIRATEK REPORTS SECOND QUARTER SALES AND EARNINGS
 COSTA MESA, Calif., Aug. 7 /PRNewswire/ -- Viratek Inc.


(NASDAQ: VIRA) said today an increase in research and development expenses reduced net income in the second quarter.
 Net income of $152,000, or 1 cent a share, on revenues of $265,000 in the second quarter, compared to net income of $269,000, or 2 cents a share, on revenues of $260,000 in the second quarter of 1991.
 Net income of $1.5 million, or 11 cents a share, on revenues of $2.3 million for the first six months of 1992 compared with net income of $628,000, or 4 cents a share, on revenues of $1.5 million for the first half of 1991.
 The company said research and development expenses increased as a result of its decision to accelerate R&D programs this year, following a reduction in recent years. As part of its renewed research activities in 1992, Viratek is developing new biomedical and diagnostic products. Viratek will receive royalties on any future sales of products developed under this program.
 Viratek currently receives royalties from SPI Pharmaceuticals Inc. for worldwide sales of the antiviral Virazole, for which Viratek holds the patent. Virazole is authorized in more than 40 nations for a total of eight indications, including hepatitis, herpes, childhood diseases such as chicken pox and measles, and influenza. In the United States, it is authorized in aerosol form for the treatment of infants hospitalized with severe lower respiratory tract infection cause by respiratory syncytial virus.
 Viratek Inc. specializes in the development and licensing of new pharmaceutical compounds from nucleic acid research. Viratek is a subsidiary of ICN Pharmaceuticals Inc., as is ICN Biomedicals and SPI Pharmaceuticals.
 VIRATEK INC.


Summary Financial Information for the Three and Six Months Ended
 June 30, 1992 and 1991
 (000s omitted except per share amounts)
 (Unaudited)
 Three months ended Six months ended
 June 30, June 30,
 1992 1991 1992 1991
 Total revenues $265 $260 $2,258 $1,504
 Net income $152 $269 $1,540 $628
 Per share information:
 Net income $0.01 $0.02 $0.11 $0.04
 Shares used in per share
 computation 14,507 14,358 14,541 14,318
 -0- 8/7/92
 /CONTACT: Jack Sholl of Viratek, 714-545-0100, ext. 3013/
 (VIRA) CO: Viratek Inc. ST: California IN: MTC SU: ERN


AH-EH -- LA006 -- 8217 08/07/92 18:14 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 7, 1992
Words:398
Previous Article:MISSOURI HIGHWAY & TRANSPORTATION COMMISSION CERTIFICATES OF PARTICIPATIONS RATED 'AA-' BY FITCH -- FITCH FINANCIAL WIRE --
Next Article:PUGET SOUND MULTIPLE LISTING ASSOCIATION SUMMARIZES FIRST HALF OF 1992 PUGET SOUND REALTY MARKET
Topics:


Related Articles
ICN PHARMACEUTICALS REPORTS RECORD FIRST QUARTER SALES AND EARNINGS; LONG-TERM LIABILITIES REDUCED BY $40 MILLION
VIRATEK REPORTS HIGHER THIRD QUARTER AND NINE-MONTH EARNINGS
VIRATEK REPORTS 1992 RESULTS
VIRATEK REPORTS FIRST QUARTER EARNINGS
VIRATEK REPORTS SECOND QUARTER RESULTS; INCREASES RESEARCH AND DEVELOPMENT
ICN PHARMACEUTICALS REPORTS SECOND QUARTER RESULTS
VIRATEK REPORTS THIRD QUARTER PROFIT; CONTINUES HEPATITIS C CLINICAL TRIALS; VIRAZOLE NOW NUMBER ONE ANTIVIRAL IN MEXICO
ICN PHARMACEUTICALS REPORTS CONSOLIDATED FIRST QUARTER 1994 RESULTS
SPI PHARMACEUTICALS POSTS STRONG SECOND QUARTER SALES AND INCOME GAINS
ICN PHARMACEUTICALS REPORTS CONSOLIDATED SECOND QUARTER 1994 RESULTS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters